Here, we use a pH-reporter system and find that nerve injury triggers a reorganization of excitatory synapses that is influenced by the accumulation of the ganglioside GT1b at afferent terminals. GT1b ...

--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

For hematologic cancers, the past decade was marked by the rise of alternative immunotherapies such as antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric ...

1Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

Led by Arthur Lahr, Avidicure is developing dual agonistic, multifunctional, and avidity-engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. The ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...